Trillium Asset Management LLC grew its position in Celgene Co. (NASDAQ:CELG) by 1.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 132,583 shares of the biopharmaceutical company’s stock after acquiring an additional 1,363 shares during the period. Celgene comprises approximately 1.1% of Trillium Asset Management LLC’s investment portfolio, making the stock its 24th biggest position. Trillium Asset Management LLC’s holdings in Celgene were worth $19,333,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the business. Thompson Davis & CO. Inc. raised its position in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI raised its position in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the last quarter. Guidant Wealth Advisors acquired a new position in shares of Celgene during the 3rd quarter worth about $119,000. Motco raised its position in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new position in shares of Celgene during the 2nd quarter worth about $129,000. Institutional investors and hedge funds own 79.74% of the company’s stock.
CELG has been the subject of several research reports. Cowen reaffirmed a “buy” rating and set a $150.00 price objective on shares of Celgene in a research note on Tuesday, September 12th. Bank of America reaffirmed a “buy” rating on shares of Celgene in a research note on Wednesday, September 13th. Royal Bank of Canada initiated coverage on shares of Celgene in a research note on Thursday, September 14th. They set a “top pick” rating and a $176.00 price objective for the company. Mizuho upped their price objective on shares of Celgene from $134.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and twenty-one have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $132.59.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company posted $1.58 EPS. analysts expect that Celgene Co. will post 6.68 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Trillium Asset Management LLC Has $19.33 Million Holdings in Celgene Co. (CELG)” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/01/05/trillium-asset-management-llc-has-19-33-million-holdings-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.